Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.
作者信息
Dieci M V, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu M C, Delaloge S, Curigliano G, Andre F
机构信息
INSERM Unit U981, Institut Gustave Roussy, Villejuif, France Department of Oncological and Surgical Sciences, University of Padua, Padua Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova.
Early Drug Development for Innovative Therapies Division, Department of Medicine, Istituto Europeo di Oncologia, Milano.
出版信息
Ann Oncol. 2015 Jul;26(7):1518. doi: 10.1093/annonc/mdv241.
Abstract
摘要
相似文献
1
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.三阴性乳腺癌初次化疗后肿瘤浸润淋巴细胞对残留病灶的预后价值：一项回顾性多中心研究
Ann Oncol. 2015 Jul;26(7):1518. doi: 10.1093/annonc/mdv241.
2
Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.三阴性乳腺癌新辅助化疗后残留肿瘤中肿瘤浸润性CD8 +和FOXP3 +淋巴细胞的预后意义及这些参数的变化：一项回顾性多中心研究
Breast Cancer Res. 2015 Sep 4;17(1):124. doi: 10.1186/s13058-015-0632-x.
3
Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.原发性全身化疗后丰富的肿瘤浸润淋巴细胞预示着雌激素受体阳性/HER2 阴性乳腺癌预后不良。
Breast Cancer Res Treat. 2018 Feb;168(1):135-145. doi: 10.1007/s10549-017-4575-z. Epub 2017 Nov 22.
4
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.两项III期随机辅助乳腺癌试验中肿瘤浸润淋巴细胞的预后和预测价值
Ann Oncol. 2015 Aug;26(8):1698-704. doi: 10.1093/annonc/mdv239. Epub 2015 May 20.
5
Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer.肿瘤浸润淋巴细胞浸润程度是三阴性浸润性乳腺癌新辅助治疗反应和总生存的更好预测指标。
Hum Pathol. 2018 Oct;80:47-54. doi: 10.1016/j.humpath.2018.05.024. Epub 2018 Jun 5.
6
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.肿瘤浸润淋巴细胞（TILs）是国际乳腺癌研究组（IBCSG）III期随机临床试验22-00中三阴性乳腺癌患者的一个有力预后标志物。
Breast Cancer Res Treat. 2016 Jul;158(2):323-31. doi: 10.1007/s10549-016-3863-3. Epub 2016 Jul 2.
7
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.一种基因特征可预测三阴性乳腺癌患者新辅助化疗后肿瘤浸润淋巴细胞高和结局。
Ann Oncol. 2018 Jan 1;29(1):162-169. doi: 10.1093/annonc/mdx691.
8
PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.新辅助化疗后局部晚期乳腺癌中残留肿瘤的程序性死亡受体配体1（PD-L1）表达作为一种预后标志物。
Int J Cancer. 2017 Mar 15;140(6):1384-1395. doi: 10.1002/ijc.30552.
9
The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.肿瘤-宿主界面处肿瘤浸润淋巴细胞的CD4/CD8比值在三阴性乳腺癌中具有预后价值。
Hum Pathol. 2017 Nov;69:110-117. doi: 10.1016/j.humpath.2017.09.012. Epub 2017 Oct 6.
10
MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.MxA表达与肿瘤浸润淋巴细胞相关，是三阴性乳腺癌的一个预后因素。
Breast Cancer Res Treat. 2016 Apr;156(3):597-606. doi: 10.1007/s10549-016-3786-z. Epub 2016 Apr 13.
引用本文的文献
1
Microenvironmental alkalization promotes the therapeutic effects of MSLN-CAR-T cells.微环境碱化促进 MSLN-CAR-T 细胞的治疗效果。
J Immunother Cancer. 2024 Oct 21;12(10):e009510. doi: 10.1136/jitc-2024-009510.
2
Immunogenic chemotherapy: great potential for improving response rates.免疫原性化疗：提高缓解率的巨大潜力。
Front Oncol. 2023 Dec 6;13:1308681. doi: 10.3389/fonc.2023.1308681. eCollection 2023.
3
Crosstalk between triple negative breast cancer and microenvironment.三阴性乳腺癌与微环境的相互作用。
Oncotarget. 2023 Mar 31;14:284-293. doi: 10.18632/oncotarget.28397.
4
SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival.SDF-1 表达和肿瘤浸润淋巴细胞可识别三阴性乳腺癌的临床亚型，这些亚型对新辅助化疗和生存的反应不同。
Front Immunol. 2022 Oct 20;13:940635. doi: 10.3389/fimmu.2022.940635. eCollection 2022.
5
Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.新辅助化疗耐药的早期高转移风险乳腺癌中与 NK、中性粒细胞和 B 细胞免疫表型相关的动态变化。
Clin Cancer Res. 2022 Oct 14;28(20):4494-4508. doi: 10.1158/1078-0432.CCR-22-0543.
6
The Immune Microenvironment in Gastric Cancer: Prognostic Prediction.胃癌中的免疫微环境：预后预测
Front Oncol. 2022 Apr 28;12:836389. doi: 10.3389/fonc.2022.836389. eCollection 2022.
7
Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions.精准医学与三阴性乳腺癌：现状与未来方向
Cancers (Basel). 2021 Jul 26;13(15):3739. doi: 10.3390/cancers13153739.
8
VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer.VEGF-A 与原发性乳腺癌中 TILs 和 PD-L1 表达的程度相关。
In Vivo. 2020 Sep-Oct;34(5):2641-2646. doi: 10.21873/invivo.12082.
9
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.三阴性乳腺癌的展望：当前治疗策略、未满足的需求及未来治疗的潜在靶点
Cancers (Basel). 2020 Aug 24;12(9):2392. doi: 10.3390/cancers12092392.
10
Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.曲妥珠单抗新辅助化疗后残余肿瘤中浸润淋巴细胞对 HER2 阳性乳腺癌的预后价值。
Sci Rep. 2019 Feb 7;9(1):1583. doi: 10.1038/s41598-018-38272-1.
Zotero 插件